Saga Bio, Inc. is a translational immunology and immunodiagnostics company. Our first project is development of point of care diagnostic tools for febrile children, and specifically Kawasaki Disease, based on sTNFR2 and vascular chemokines. We also have therapeutic monoclonal antibodies, humanized, for intervention in inflammatory diseases in the preclinical stage of development.